These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 25403247)

  • 1. Bladder cancer: On the dot--targeted molecular imaging.
    Stone L
    Nat Rev Urol; 2015 Jan; 12(1):6. PubMed ID: 25403247
    [No Abstract]   [Full Text] [Related]  

  • 2. Endoscopic molecular imaging of human bladder cancer using a CD47 antibody.
    Pan Y; Volkmer JP; Mach KE; Rouse RV; Liu JJ; Sahoo D; Chang TC; Metzner TJ; Kang L; van de Rijn M; Skinner EC; Gambhir SS; Weissman IL; Liao JC
    Sci Transl Med; 2014 Oct; 6(260):260ra148. PubMed ID: 25355698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles: take only pictures, leave only footprints.
    Choyke PL
    Sci Transl Med; 2014 Oct; 6(260):260fs44. PubMed ID: 25355696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Endoscopic Molecular Imaging of Human Bladder Cancer Using a CD47 Antibody.
    Chang SS
    J Urol; 2016 Apr; 195(4 Pt 1):1170. PubMed ID: 27302826
    [No Abstract]   [Full Text] [Related]  

  • 5. CD47 blockade as another immune checkpoint therapy for cancer.
    Vonderheide RH
    Nat Med; 2015 Oct; 21(10):1122-3. PubMed ID: 26444633
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
    Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
    Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
    Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
    Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
    Sockolosky JT; Dougan M; Ingram JR; Ho CC; Kauke MJ; Almo SC; Ploegh HL; Garcia KC
    Proc Natl Acad Sci U S A; 2016 May; 113(19):E2646-54. PubMed ID: 27091975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.
    Liu X; Pu Y; Cron K; Deng L; Kline J; Frazier WA; Xu H; Peng H; Fu YX; Xu MM
    Nat Med; 2015 Oct; 21(10):1209-15. PubMed ID: 26322579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer.
    Zhang X; Fan J; Wang S; Li Y; Wang Y; Li S; Luan J; Wang Z; Song P; Chen Q; Tian W; Ju D
    Cancer Immunol Res; 2017 May; 5(5):363-375. PubMed ID: 28351890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
    Horrigan SK;
    Elife; 2017 Jan; 6():. PubMed ID: 28100392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma.
    Lo J; Lau EY; So FT; Lu P; Chan VS; Cheung VC; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
    Liver Int; 2016 May; 36(5):737-45. PubMed ID: 26351778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Surgical treatment of urinary bladder cancer].
    Lopatkin NA; Martov AG; Darenkov SP; Kamalov AA; Kudriavtsev IuV
    Urol Nefrol (Mosk); 1999; (1):26-31. PubMed ID: 11149341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD47 limits antibody dependent phagocytosis against non-malignant B cells.
    Gallagher S; Turman S; Lekstrom K; Wilson S; Herbst R; Wang Y
    Mol Immunol; 2017 May; 85():57-65. PubMed ID: 28208074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and therapy of bladder tumors].
    Mazzitelli M; Santorelli V
    Minerva Urol; 1981; 33(3):125-8. PubMed ID: 7322103
    [No Abstract]   [Full Text] [Related]  

  • 18. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
    Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potentiating effect of hTFPI in the presence of hCD47 reduces the cytotoxicity of human macrophages.
    Jung SH; Hwang JH; Kim SE; Young Kyu K; Park HC; Lee HT
    Xenotransplantation; 2017 May; 24(3):. PubMed ID: 28393401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor CD47 controls T cell alloresponses and is required for tolerance induction following hepatocyte allotransplantation.
    Zhang M; Wang H; Tan S; Navarro-Alvarez N; Zheng Y; Yang YG
    Sci Rep; 2016 May; 6():26839. PubMed ID: 27230788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.